Filip Janku Increases Stake in Monte Rosa Therapeutics
Chief Medical Officer Filip Janku purchased 6,000 shares of Monte Rosa Therapeutics.
Key Points
- On June 29, 2026, Filip Janku, the Chief Medical Officer of Monte Rosa Therapeutics, bought 6,000 shares at $7.56 each, totaling $45,360.
- Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE) traded at $24.20 on Wednesday, with a market cap of approximately $2.04 billion and a 52-week high of $25.77.
- Analysts maintain a buy rating on Monte Rosa Therapeutics, with Guggenheim setting a price target of $35 as of June 30, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Filip Janku, the Chief Medical Officer of Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE), recently increased his stake in the company. On June 29, 2026, Janku bought 6,000 shares at an average price of $7.56 each, bringing the total value of the transaction to $45,360. This purchase was not made under a pre-planned trading program.
Insider Buying and Selling at Monte Rosa Therapeutics, Inc.
On the same day, Janku also sold 6,000 shares at a price of $22.95, though this transaction was planned. Additionally, Anthony Manning, another insider, bought 10,000 shares at $4.16 and sold the same amount at $23.11, both on June 29, 2026.
Monte Rosa Therapeutics, Inc. Stock Up 80.9%
Shares of Monte Rosa Therapeutics traded around $24.20 on Wednesday. The company, which operates in the biotechnology sector, has a market capitalization of about $2.04 billion. It has a 52-week low of $4.12 and a high of $25.77. The stock's 50-day moving average is $19.09, while the 200-day moving average stands at $16.34. The company has a current ratio of 9.54, indicating strong liquidity, and a debt-to-equity ratio of 7.49.
$GLUE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts continue to show confidence in Monte Rosa Therapeutics. On June 30, 2026, Guggenheim maintained its buy rating, setting a price target of $35. Other firms like JP Morgan and Piper Sandler have also reiterated their buy ratings, with targets of $31 and $37, respectively. The consensus target price is around $32.33, based on six analyst opinions.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. It focuses on developing small molecule precision medicines that use the body's natural processes to target and degrade specific proteins. The company is working on treatments for various conditions, including MYC-driven tumors and autoimmune diseases. Led by CEO Dr. Markus Warmuth, Monte Rosa employs 187 people and has collaborations with major firms like F. Hoffmann-La Roche Ltd. and Novartis.
Bottom Line
Insider buying can indicate confidence in a company's future, and Filip Janku's recent stock purchase adds to this narrative for Monte Rosa Therapeutics. The company's innovative approach to biotechnology, coupled with strong analyst support, makes it a stock to watch. Keep in mind, however, that 13F filings and insider trades may not reflect current positions.
Get Monte Rosa Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GLUE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.